Traditionally, patients who require medication only available in invasive delivery forms, have difficulty swallowing pills, or with psychiatric or physiological conditions have had to endure challenges to meet the requirements of prescribed dosing regimens in traditional delivery forms. PharmFilm®, a leading-edge pharmaceutical dosage form, delivers existing prescription products directly to the bloodstream with potentially improved efficacy, palatability and speed. Together with development and marketing partners, targets are selected based upon technical suitability for the Company's PharmFilm® drug delivery platform, patent expiration, patient demographics, approved indications and other factors.
For certain drugs, MonoSol Rx’s PharmFilm® drug delivery technology may improve therapeutic efficacy through faster onset of action or lower dosing which may also result in reduced side effects and improved safety. The potential to deliver prescription drugs with improved therapeutics, compounded with PharmFilm®’s value as a market differentiator, is attractive to our existing and potential pharmaceutical partners.
|INDICATION||APPROVAL DATE||MARKETING PARTNER|
|Treatment of Nausea & Vomiting||July 2010||Midatech|
|Treatment of Opioid Dependence||August 2010||INDIVIOR|